Stoke Therapeutics

STOK62

$12.03arrow_drop_down13.57%-$1.89

STOK62

$12.03

arrow_drop_down13.57%-$1.89

Performance History

Key Stats
Open	$13.88
Prev. Close	$13.92
EPS	-2.08
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	11.77	14.44
52 Week Range	3.35	17.58

Ratios







EPS	-2.08

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Stoke Therapeutics (STOK)

Stoke Therapeutics Inc (STOK) is a biotechnology company focused on the development of treatments for severe genetic diseases. The company's approach is based on the modulation of gene expression to increase the production of target proteins. By targeting specific genetic mutations, Stoke aims to restore protein levels and thereby alleviate disease symptoms. The company's lead candidate, STK-001, is being developed for the treatment of Dravet syndrome, a rare neurological disorder characterized by severe seizures. STK-001 has shown promising results in preclinical studies and is currently in Phase 1/2 clinical trials.

In addition to Dravet syndrome, Stoke Therapeutics is also exploring the potential of its platform technology in other genetic disorders, including genetic epilepsy, genetic ataxia, and genetic ALS. The company's strategy involves leveraging its deep understanding of RNA biology and proprietary gene therapy platform to develop novel treatments for these challenging diseases. Stoke's unique approach has attracted significant attention from investors and collaborators. The company has formed partnerships with major pharmaceutical companies, including Novartis, to further advance its pipeline.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Edward M. Kaye M.D., Ph.D.
Headquarters: Bedford
Employees: 117
Exchange: NASDAQ

Keep an eye on Stoke Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is the 52-week high and low for Stoke Therapeutics (STOK)?

For Stoke Therapeutics (STOK), the 52-week high is $17.58, which is 46.13% from the current price. The 52-week low is $3.35, the current price is 259.1% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Stoke Therapeutics (STOK) a growth stock?

Stoke Therapeutics (STOK) has shown an average price growth of -4.94% over the past three years. It has received a score of 81 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Stoke Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Stoke Therapeutics (STOK) stock price performance year to date (YTD)?

As of the latest data, Stoke Therapeutics (STOK) has a year-to-date price change of 105.29%. Over the past month, the stock has experienced a price change of -5.2%. Over the last three months, the change has been -15.58%. Over the past six months, the figure is -14.86%. Looking at a longer horizon, the five-year price change stands at -48.41%.

help

Is Stoke Therapeutics (STOK) a profitable company?

Stoke Therapeutics (STOK) has a net income of -$104.7M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 46.14% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -613.06% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $8.78M, although specific revenue growth data is currently not available. The gross profit is $4.05M. Operating income is noted at -$114.77M. Furthermore, the EBITDA is -$115.03M.

help

What is the market capitalization of Stoke Therapeutics (STOK)?

Stoke Therapeutics (STOK) has a market capitalization of $637.19M. The average daily trading volume is 12.57, indicating the stock's liquidity and investor engagement.

help

What is Stoke Therapeutics 's (STOK) price per share?

The current price per share for Stoke Therapeutics (STOK) is $12.03. The stock has seen a price change of -$1.89 recently, indicating a -13.58% change. This reflects the stock's recent market performance and investor sentiment.